Durect Corp: Jumps after FDA approves non-opiod painkiller

DURECT

02/02/2021 13:28

**  Shares of the drug developer  DRRX.O  rise 38% to $2.90
premarket - set for over one-year high if gains hold
    ** DRRX says the U.S. FDA approved its non-opiod painkiller
Posimir to manage post-surgical pain following a type of
shoulder surgery   urn:newsml:reuters.com:*:nPn5RVt28a
    ** An independent panel of experts last month were split
over the approval of Posimir, with six members voting in favor
of recommending the drug, while an equal number were against
it urn:newsml:reuters.com:*:nL4N29M2Z8
    ** Stock up 1.5% YTD as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))